NCT06005324View on ClinicalTrials.gov

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
HPV-Negative Squamous Cell Carcinoma
Interventions
DRUG

Paclitaxel

Given as part of induction chemotherapy.

DRUG

Carboplatin

Given as part of induction chemotherapy.

DRUG

Cetuximab

Given as part of induction chemotherapy.

RADIATION

Standard Dose Radiation

Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.

RADIATION

Low Dose Radiation

Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.

DRUG

Cisplatin

Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

DRUG

TFHX Regimen

Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

Trial Locations (1)

60637

RECRUITING

University of Chicago Medicine Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER